PT-141 (Bremelanotide) Adolescent (12 to 17) Monitoring

Why Bremelanotide Has No Adolescent Indication

Bremelanotide received FDA approval in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. The label is narrow by design. HSDD is a diagnosis applied to adults, and the condition has no recognized pediatric equivalent in current diagnostic frameworks.

The RECONNECT Trial Population

The two key RECONNECT phase III trials (Kingsberg et al., 2019) enrolled 1,247 premenopausal women aged 18 to 55. These trials demonstrated statistically significant improvements in sexual desire and reductions in distress compared with placebo over 24 weeks. No participants under 18 were included, and no extension studies have enrolled adolescents.

Regulatory Position on Pediatric Use

The FDA's Pediatric Research Equity Act (PREA) can require manufacturers to study drugs in pediatric populations when the adult indication may apply to children. Because HSDD is not diagnosed in minors, the FDA did not mandate pediatric studies for bremelanotide. The product label states: "Safety and effectiveness in pediatric patients have not been established." This is not a gap awaiting data. It reflects the absence of a clinical rationale for routine pediatric use.

Off-Label Prescribing Reality

Despite this, melanocortin receptor agonists have generated research interest in adolescent populations for other conditions, including obesity and rare genetic disorders. Setmelanotide, a related MC4R-pathway drug, received FDA approval for pediatric obesity caused by POMC, PCSK1, or LEPR deficiency. Bremelanotide is pharmacologically distinct from setmelanotide, and clinical findings from one agent should not be extrapolated to the other without direct evidence.

Cardiovascular Monitoring Requirements

Blood pressure management is the single most emphasized safety concern on the Vyleesi label. In adult RECONNECT participants, bremelanotide 1.75 mg produced transient systolic blood pressure increases averaging 6 mmHg, with some patients experiencing rises exceeding 12 mmHg within 2 to 3 hours of injection.

Why Adolescents Need Closer Hemodynamic Tracking

Adolescent blood pressure norms differ from adult values. The American Academy of Pediatrics (AAP) 2017 guidelines define hypertension in children as blood pressure at or above the 95th percentile for age, sex, and height. A 6 to 12 mmHg systolic spike that falls within normal range for a 35-year-old woman could push a 14-year-old into stage 1 or stage 2 hypertension territory depending on baseline.

Recommended Protocol

Any clinician considering off-label bremelanotide in an adolescent should, at minimum:

• Obtain baseline blood pressure on three separate occasions before the first dose
• Measure blood pressure at 30, 60, and 120 minutes after the initial injection
• Repeat in-office monitored dosing for at least the first three administrations
• Discontinue if systolic blood pressure exceeds the 95th percentile for age/sex/height on two consecutive readings

Patients with pre-existing hypertension or cardiovascular disease are explicitly contraindicated per the FDA label, regardless of age.

Melanocortin Receptor Effects on Growth and Development

Bremelanotide activates MC4R and, to a lesser extent, MC3R and MC1R. These receptors are not confined to sexual function pathways. They regulate energy homeostasis, adrenal function, and melanogenesis across multiple organ systems.

Neuroendocrine Considerations

MC4R signaling is involved in hypothalamic-pituitary-adrenal (HPA) axis regulation. During adolescence, the HPA axis undergoes significant maturation. Exogenous MC4R activation could theoretically alter cortisol rhythms, growth hormone pulsatility, or pubertal timing, though no human data confirm or refute this for bremelanotide specifically. The Endocrine Society's guidelines on puberty emphasize that medications affecting hypothalamic signaling pathways warrant monitoring of Tanner staging and growth velocity in adolescents.

Growth Velocity and Pubertal Staging

If bremelanotide is administered off-label to a patient aged 12 to 17, monitoring should include:

• Tanner stage assessment at baseline and every 6 months
• Height velocity tracked against CDC growth charts at each visit
• Bone age radiograph at baseline if the patient is pre- or mid-pubertal (Tanner 2 to 3)
• Serum IGF-1 and morning cortisol at baseline and at 3-month intervals

These measures establish whether MC4R agonism is producing detectable effects on the developing endocrine system. No published case series has reported growth disruption from bremelanotide, but the absence of data is not evidence of safety.

Pigmentation Monitoring

Bremelanotide activates MC1R, the primary melanocortin receptor governing melanin synthesis. In the RECONNECT trials, approximately 1% of women developed focal skin hyperpigmentation, most commonly on the face, gingiva, and breasts. Pigmentation changes were generally reversible after discontinuation but persisted in some cases.

Adolescent-Specific Concerns

Adolescent skin undergoes hormonally driven pigmentation shifts during puberty. Adding an exogenous MC1R agonist could complicate clinical differentiation between drug-induced hyperpigmentation and normal developmental changes such as areolar darkening or linea nigra. A structured approach includes:

• Baseline full-body skin photography with standardized lighting
• Oral mucosal examination at every visit (gingival pigmentation was the earliest sign in adult trials)
• Patient and parent education about reporting new or changing moles, dark patches, or gum discoloration
• Dermatology referral if any pigmented lesion is atypical or growing

The FDA label notes that bremelanotide should not be used in patients with a history of melanoma or in those at high risk. Adolescents with dysplastic nevus syndrome, a family history of melanoma, or fair skin (Fitzpatrick types I, II) require particularly careful risk-benefit assessment.

Mental Health and Behavioral Monitoring

Prescribing a drug developed for adult sexual desire disorder to a minor raises clinical and ethical dimensions that extend well beyond pharmacology. Mental health monitoring is not optional in this population.

Neuropsychiatric Signals in Adults

In the RECONNECT trials, nausea occurred in approximately 40% of bremelanotide-treated women, and hot flush in 20%. Neuropsychiatric adverse events were less common but included headache, fatigue, and dizziness. No completed suicides or suicide attempts were reported in the trial database. Depression and anxiety were tracked but did not differ significantly from placebo.

Why Adolescents Require Enhanced Screening

The adolescent brain is undergoing prefrontal cortical maturation, with incomplete myelination of circuits governing impulse control, emotional regulation, and reward processing. MC4R is expressed in limbic structures including the amygdala and hypothalamus. While bremelanotide's blood-brain barrier penetration is limited, the possibility of central nervous system effects cannot be excluded without pediatric pharmacokinetic data.

Monitoring should include:

• PHQ-A (Patient Health Questionnaire for Adolescents) at baseline and monthly for the first 3 months, then quarterly
• Columbia Suicide Severity Rating Scale (C-SSRS) at each clinical contact
• Assessment of disordered eating behaviors, given MC4R's role in appetite regulation
• Documentation of the clinical rationale for prescribing, including why alternative interventions were insufficient

Any emergent suicidal ideation, self-harm behavior, or rapid mood change warrants immediate discontinuation and psychiatric evaluation.

Hepatic and Renal Considerations

Bremelanotide is metabolized via hydrolysis, not hepatic CYP450 enzymes, and is primarily excreted renally. In adults with mild-to-moderate hepatic impairment, no dose adjustment was required in pharmacokinetic studies. No data exist for adolescents with hepatic or renal disease.

Baseline and Ongoing Labs

A reasonable monitoring panel for adolescent patients includes:

| Parameter | Timing | |---|---| | Comprehensive metabolic panel | Baseline, then every 3 months | | CBC with differential | Baseline, then every 6 months | | Urinalysis | Baseline, then every 6 months | | Serum cortisol (morning) | Baseline, then every 3 months | | IGF-1 | Baseline, then every 3 months | | Lipid panel | Baseline, then annually | | HbA1c | Baseline if BMI above 85th percentile |

These intervals are more frequent than what the adult label requires, reflecting the absence of established safety data in the 12 to 17 age group.

Informed Consent and Documentation

Off-label prescribing to minors carries heightened medicolegal responsibilities. Both the patient and guardian must participate in the consent process.

Elements of Valid Informed Consent

The consent discussion and documentation should cover:

• Explicit statement that bremelanotide is not FDA-approved for any indication in patients under 18
• Description of known adult adverse effects (nausea, flushing, injection-site reactions, transient hypertension, hyperpigmentation)
• Acknowledgment that long-term effects on growth, puberty, mood, and fertility are unknown
• Alternative treatments considered and the clinical reasoning for selecting bremelanotide
• A clear discontinuation plan with defined safety thresholds

The American Academy of Pediatrics policy on informed consent recommends documenting both parental permission and adolescent assent as separate elements when treating minors, particularly for off-label medications.

Drug Interactions Relevant to Adolescents

Bremelanotide does not undergo CYP-mediated metabolism, limiting traditional drug-drug interaction risk. The FDA label identifies one clinically significant interaction: co-administration with oral naltrexone reduced bremelanotide's effectiveness in adult trials.

Medications Common in Adolescent Populations

Several drug classes frequently prescribed to teenagers deserve specific attention:

• SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine): No pharmacokinetic interaction expected, but both SSRIs and bremelanotide affect central nervous system pathways. Additive nausea is likely. Monitor for serotonin-related symptoms.
• Stimulants (methylphenidate, amphetamine): Both stimulants and bremelanotide raise blood pressure transiently. The combination could produce additive hypertensive effects requiring more frequent cardiovascular monitoring.
• Oral contraceptives: Bremelanotide slowed gastric emptying in adult studies, which reduced the absorption rate of orally administered drugs. The FDA label recommends administering oral medications at least 1 hour before or 2 hours after a bremelanotide injection. For adolescents relying on oral contraceptives, this timing matters.
• Isotretinoin: Both isotretinoin and bremelanotide carry mucosal and skin-related effects. Concurrent use has not been studied.

When to Discontinue

Clear stopping rules protect patients from prolonged exposure to a medication with no established benefit in their age group.

Mandatory Discontinuation Triggers

Bremelanotide should be stopped immediately if any of the following occur:

1. Systolic blood pressure exceeds the 95th percentile on two consecutive in-office readings
2. New focal hyperpigmentation that is expanding or atypical in morphology
3. PHQ-A score increases by 5 or more points from baseline
4. Positive screen on the Columbia Suicide Severity Rating Scale
5. Evidence of disordered eating behavior (restriction, bingeing, or purging)
6. Tanner staging that deviates from expected progression by more than one stage in either direction over 6 months
7. Patient or guardian withdraws consent

Dose adjustment is not an appropriate response to these triggers in an unapproved population. The correct action is discontinuation and clinical reassessment.

Bremelanotide 1.75 mg SC has a half-life of approximately 2.7 hours in adults, meaning drug clearance following discontinuation is rapid. Monitoring should continue for at least 30 days after the last dose to capture any delayed effects on pigmentation or mood.